Irum  Khan

840 S. Wood St, 820-E CSB

Chicago, IL 60612

Ph. (312) 355-5419 Fax (312) 413-4131

irumkhan@uic.edu

Education

2020                  MS in Clinical and Translational Science, University of Illinois, Chicago, Illinois

2009-2012        Fellowship in Hematology and Oncology, Northwestern University, Chicago, Illinois

2005-2008        Internal Medicine Residency, University of Cincinnati, OH

1998-2003        M.B., B.S., Aga Khan University Medical College, Karachi,

Pakistan

Experience

2020 to date    Associate Professor of Clinical Medicine

Associate Director for Academic Programs (fellowship)

Dept. of Medicine, Section of Hematology/Oncology

University of Illinois, Chicago, IL 

2013-2019      Assistant Professor of Clinical Medicine

Dept. of Medicine, Section of Hematology/Oncology

    University of Illinois, Chicago, IL 

2010-2012        Research Fellow

Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

Principal Investigator: John D Crispino PhD.

• Inhibition of PI3K/AKT signaling as a therapeutic strategy in myeloproliferative neoplasms

2008-2009        Hospitalist

Louisville Inpatient Physician Services, Norton Hospital, Louisville, KY

2006                  Research Assistant (3 months)

Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital, Cincinnati, OH

Principal Investigator: David A Williams MD.

• Understanding the role of the Rac GTPase isoform Rac3 in hematopoiesis

2004-2005        Research Assistant

Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, MA

Principal Investigator: Fotini Gounari PhD.

• Defining the role of c-myc in thymocyte development

Other Experience and Professional Memberships

2021-22    NIH Developmental Therapeutics Study Section Early Career Reviewer

2021-23    American Society of Hematology Friday Satellite Symposia Study Section                                     Chair

2021         Author: American Society of Hematology-Self-Assessment Program 8^th ed. 

2019-        Co-Chair Myeloid Committee, the Big Ten Cancer Research Consortium

2019-        UIC-CCTS KL2 grant reviewer

2018          Author: American Society of Hematology-Self-Assessment Program 7^th ed.  2018-           Leukemia Research Foundation (LRF) Grant Review Committee

2020-        Ad hoc reviewer: American Journal of Hematology, PLOS One, 

Leukemia and Lymphoma, Blood Cancer Journal, Blood Advances, BBMT

2014-         Protocol Review Committee-University of Illinois

2013-17    Leukemia and Lymphoma Society (LLS) Chicago Steering Committee

2013-16    MPN-Research Foundation: Chicago MDS-MPN rounds steering   

                  committee

2009-        Diplomate, American Boards of Internal Medicine, Hematology and Oncology

2009-        Member, American Society of Hematology

Honors/Awards

2019          MPN Hero Award-CURE foundation

2019         Univ. of Illinois Chicago-UI Health Physician of the Year Nominee

2018         Univ. of Illinois Hematology/Oncology Fellowship Mentor of the Year Award

2016         Univ. of Illinois Hematology/Oncology Fellowship Teacher of the Year Award

2016         Leukemia Lymphoma Society (Illinois Chapter) Physician of the Year

2011         ASH–EHA Translational Research Training in Hematology (TRTH) Award 2011         ASH Abstract Achievement Award

Invited lectures/panels

2.7.21        ‘Management of AML in transplant ineligible patients’

                   2^nd Annual Hematology Meeting

                   Society of Medical Oncology Pakistan

   10.24.20     Outcomes of BRIGHT AML 1003

                   ASCO Direct United Arab Emirates  2020 Webinar                   

5.29.20      ‘Targeted Interventions in Relapse/Refractory Leukemias’

                   Discussant-Poster Discussion Session,

                   ASCO Annual Meeting (virtual)

1.02.20      ‘Treatment Updates in Myeloid Malignancies’

                   Society of Medical Oncology Pakistan

                   Lahore, Pakistan

9.29.19      ‘OutFOXing Acute Myeloid Leukemia’

                   Special Seminar, Section of Hematology/Oncology

                   University of Chicago, Chicago, IL       

11.2.18     ‘Treatment Updates in MDS and MPNs’

                  Invited speaker, 17^th Shaukat Khanum Cancer Center Symposium,

                  Lahore, Pakistan

5.22.18      ‘Acute Myeloid Leukemia-the rocky road to progress’

                  Department of Medicine Grand Rounds, UIC

2.16.18      ‘Validation of FOXM1 as a therapeutic target in AML’

                   Research Seminar, Section of Hematology/Oncology, UIC

11.9.17       ‘Management of the patient with secondary AML’

                   Leukemia and Lymphoma Society AML rounds, Chicago, IL

6.13.17       ‘FLT3-mutated AML’

                   Leukemia and Lymphoma Society AML rounds, Chicago, IL

3.25.17       Myeloid Malignancies Panel Discussion Chair

                   Leukemia Lymphoma Society Clinical Trials Symposium, Chicago, IL

11.19.15    ‘Del 5q Syndrome’            

                   MDS/MPN Rounds sponsored by AAMDS/MPN-Research Foundations

3.14.15       Myeloid Malignancies Panel Discussion Chair

                   Leukemia Lymphoma Society Clinical Trials Symposium, Chicago, IL

3.18.14      ‘Pegylated Interferon in Polycythemia Vera’                

                  AAMDS/MPN-Research Foundation MDS/MPN Rounds, Chicago, IL

9.13.13     ‘Late effects of treatment for hematologic malignancies’.

                 Leukemia Lymphoma Society. Blood Cancer Conference , Oakbrook, IL

Peer reviewed publications                                                                                               

1. Khan I, Eklund EA, Gartel AL. Therapeutic vulnerabilities of transcription factors in AML.Mol Cancer Ther. 2021 Feb;20(2):229-237.
2.  Abraham IE Patel AA, Wang H, Galvin J, Frankfurt O, Liu L, Khan I. Impact of Race on Outcomes in Intermediate Risk Acute Myeloid Leukemia.  (revisions submitted to Cancer Causes & Control)
3. Singh, A, Simons, Y, Biren-Fetz, J, Mohapatra, G; Ni, H; Gaitonde, S; Khan, I. Extended treatment response to Imatinib in Rosai-Dorfman Disease. European Journal of Haematology.2021-accepted for publication 
4. An Open-Label Phase 2 Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection during Induction Chemotherapy for AML. Pinkal M. Desai, MD MPH1*; Janice Brown, MD2*; Saar Gill, MD3; … Irum Khan, MD17; … Camille N. Abboud, MD22**; Farhad Ravandi, MD23** (revised submission to JCO)
5. Stahl M, Shallis RM,..Khan I, … Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Dec;34(12):3149-3160
6. Shallis RM, Stahl M, Sekeres MA, Fathi AT, …Khan I, …Gore S, Zeidan AM et al. Patterns of care and clinical outcomes of patients with newly diagnosed  AML presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020 Feb 26:1-6.
7. Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 Aug;95(8):937-943. 
8. Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen YH, Aardsma N, Liu L, Crispino JD, Mahmud N, Frankfurt O, Gartel AL. FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018 Aug 9;3(15).
9. Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Jain S, Peace D, Quigley JG, Khan I, Molokie RE, Mahmud N, Gordeuk VR, Rondelli D. Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2018 Aug;24(8):1759-1765
10. Patel P, Oh AL, Koshy M, Sweiss K, Saraf SL, Quigley JG, Khan I, Mahmud N, Hacker E, Ozer H, Peace DJ, Weichselbaum RR, Aydogan B, Rondelli D. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 Jul;59(7):1666-1671
11. Sweiss K, Anderson J, Wirth S, Oh A, Quigley JG, Khan I, Saraf S, Mactal-Haaf C, Rondelli D, Patel P. A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. Bone Marrow Transplant. 2018 Mar;53(3):300-306.
12. Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL. Honokiol is a FOXM1 antagonist. Cell Death Dis. 2018 Jan 24;9(2):84
13. Brinda B, Khan I, Parkin B, Konig H. The rocky road to personalized medicine in acute myeloid leukaemia. J Cell Mol Med. 2018 Jan 12: 1-17.
14. Khan I, Halasi M, Zia MF, Gann P, Gaitonde S, Mahmud N, Gartel AL . FOXM1 drives chemoresistance in AML Leukemia. 2017 Jan;31(1):251- 255
15. Khan I, Saraf SL, Shergill A, Chen YF,  Patel PR, Quigley JG, Peace D Gordeuk VR, Hoffman R, Rondelli Damiano. Outcome Disparities in Caucasian and non-Caucasian Patients with Myeloproliferative Neoplasms. Clin Lymph Myeloma Leuk 2016 Mar 8.
16. Saraf SL, Oh AL, Patel PR, Peace D, Quigley JG, Khan I, Molokie RE, Hsu LL, Mahmud N, Levinson DJ, Pickard AS, Garcia JG, Gordeuk VR, Rondelli D et al. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2015 Sep 5.
17. Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Weichselbaum RR, Rondelli D et al. Combination of linear accelerator-based intensity- modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014; 20(12):2034-41.
18. Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep;27(9):1882-90
19. Khan I, Altman JK, Licht JD. New Strategies in Acute Myeloid Leukemia: Redefining prognostic markers to guide therapy. Clin Cancer Res. 2012;18(19): 5163-71
20. Khan I, Malinge S, Crispino JD. Myeloid Leukemia in Down Syndrome. Critical reviews in Oncogenesis. 2011;16(1-2):25-36
21. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology. 2010; 24(7):574-87.
22. Dose M, Khan I, Guo Z, Kovalovsky D, von Boehmer H, Khazaie K, Gounari F. c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood. 2006;108(8):2669-77

Book Chapters                                                                                                                    

1. 1. ASH Self-Assessment Program (ASH-SAP) 7^th edition. Chapter 7. Cellular basis of hematopoiesis and stem cell transplantation. Irum Khan and Kim-Hien T. Dao (2019)
   2. Cancer Consult: Expertise for Clinical Practice. Chapter 30. Hematopoietic Cell Transplantation in Primary Myelofibrosis. Khan I, Rondelli D. September 2014, Wiley-Blackwell.
   3. Contemporary Management of Myeloproliferative Neoplasms. Chapter

7. Hematopoietic Stem Cell Transplant in Myelofibrosis. Khan I, Rondelli D. Nov 2014, Jaypee Brothers Medical Publishers.

Posters and Presentations

1. Ivy Abraham, Garth Rauscher, Anand Patel, William Pearse, Priya Rajakumar, Stephanie Berg, Sushma Bharadwaj, Koosha Paydary, Maria Aceved o-Mendez, Ahmad Aleem, Kylie Carlson, Richard Gomez, Stephanie Tsai, Maryam Zia, Melissa Larson, John Quigley, Wendy Stock, Jessica Altman, Irum Khan. The Role of Structural Violence in Acute Myeloid Leukemia Outcomes. ASH Annual Meeting, Dec. 2020, (oral abstract- ASH press release)
2. Ivy Abraham, Anand Ashwin Patel, Yanyu Zhang, Li C Liu, Olga Frankfurt and Irum Khan. Impact of Race on Outcomes in intermediate risk AML. ASH Annual Meeting, Dec. 2018, Atlanta, GA
3. Irum Khan, Anand Ashwin Patel, Marianna Halasi, Rachael Schultz , Yi-Hua Chen,Nathan Aardsma, Nandini Kalakota, Li C Liu, Nadim Mahmud, Peter Gann, Olga Frankfurt, Andrei Gartel. Validation of FOXM1 as a Therapeutic Target in Acute Myeloid Leukemia. ASH Annual Meeting, Dec. 2017, Atlanta, GA (oral abstract)
4. Irum Khan, Marianna Halasi, Andrei Gartel. Inhibition of FOXM1 By Ixazomib Confers Chemosensitivity in NPM1-Wild Type Acute Myeloid Leukemia. ASH  Annual Meeting, Dec. 2016, San Diego, CA
5. Irum Khan, Maryam Zia, Marianna Halasi, Peter Gann, Sujata Gaitonde, Andrei Gartel.FOXM1 Binds Nucleophosmin in AML and Confers Resistance to Chemotherapy. ASH  Annual Meeting, Dec. 2015, Orlando, FL
6. Ardaman Shergill, Santosh L. Saraf, Sujata Gaitonde, Damiano Rondelli, Irum Khan.

CCN2 - Exploring a New Biomarker in Myelofibrosis. ASH Annual Meeting, Dec. 2015, Orlando, FL.

7. Khan I. Huang Z, Wen Q, Koppikar P, Levine R, Tefferi A, Crispino JD. Inhibition of AKT signaling potently inhibits the growth of JAK and MPL-mutant cells in the myeloproliferative neoplasms in vitro and in vivo .ASH Annual Meeting, Dec

2011, San Diego, CA

8. Khan I, Oleksowicz L. Mature Mediastinal Teratoma with Elevated Alpha-Fetoprotein in Klinefelter’s Syndrome. American College of Physicians Ohio Chapter. Oct 2007, Columbus, OH
9. Alvi S, Henderson B, Khan I, Patel S, Raza A. Involvement of Bone Marrow Stroma in the Pathogenesis of Myelodysplastic Syndromes. ASH Annual Meeting, Dec 1999, New Orleans, LA.

Research Support                                                                                                                

Active

University of Illinois Cancer Center  Director’s Pilot Program   Khan (PI)    7/1/19-6/30/21

Structural violence as a contributor to disparities in leukemia outcomes

University of Illinois Cancer Center Pilot Program   Khan (co-I)                    9/1/20-8/30/21

Novel strategies for targeting of FOXM1 in AML

Completed

Leukemia Research Foundation New Investigator Grant     Khan (PI)       7/1/19-8/30/20

Targeting FOXM1 to improve treatment responses in AML

KL2TR002002-01      Khan (Scholar)  DiPietro(PI)                                 9/16/16-9/15/18

FOXM1 is a critical downstream target of the FLT3-ITD mutation in AML.

Millenium/Takeda 083434-00001       Khan (PI)                                               9/1/16-8/30/18 Combination  treatment  with  proteasome  inhibitors  to  target  FOXM1  in  AML.

NIH 1R21CA194608-01  Gartel/Khan (PI/Co-I)                                          5/1/15-4/30/17

Cytoplasmic FOXM1 contributes to the higher complete remission and longer overall survival of AML patients after chemotherapy

UIC Cancer Center Pilot grant                 Khan (PI)                                     3/1/ 14 –2/28/15

Cytoplasmic relocalization of FOXM1 by mutant NPM may correlate with a favorable outcome for AML patients.

5T32CA079447-12                        Khan (Trainee)  Rosen (PI)                     7/1/10- 6/30/12

Targeting the PI3 kinase pathway in Myeloproliferative Neoplasms.